Your browser doesn't support javascript.
loading
Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid ß.
Mormino, Elizabeth C; Papp, Kathryn V; Rentz, Dorene M; Donohue, Michael C; Amariglio, Rebecca; Quiroz, Yakeel T; Chhatwal, Jasmeer; Marshall, Gad A; Donovan, Nancy; Jackson, Jonathan; Gatchel, Jennifer R; Hanseeuw, Bernard J; Schultz, Aaron P; Aisen, Paul S; Johnson, Keith A; Sperling, Reisa A.
Afiliação
  • Mormino EC; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Papp KV; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Neurology, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Rentz DM; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Neurology, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Donohue MC; Department of Neurology, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA.
  • Amariglio R; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Neurology, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Quiroz YT; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, USA; Department of Psychiatry, Massachusetts General Hospital, Harvard Medi
  • Chhatwal J; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Marshall GA; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Neurology, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Donovan N; Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Jackson J; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Gatchel JR; Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Hanseeuw BJ; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Schultz AP; Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, USA; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Aisen PS; Department of Neurology, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA.
  • Johnson KA; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Neurology, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Radiology, Massachusetts General Hospital, Harv
  • Sperling RA; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Neurology, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Radiology, Massachusetts General Hospital, Harv
Alzheimers Dement ; 13(9): 1004-1012, 2017 Sep.
Article em En | MEDLINE | ID: mdl-28253478
ABSTRACT

INTRODUCTION:

Sensitive detection of cognitive decline over the course of preclinical Alzheimer's disease is critical as the field moves toward secondary prevention trials.

METHODS:

We examined amyloid ß (Aß)-related change in several variations of the preclinical Alzheimer cognitive composite (PACC) and each individual PACC component in clinically normal (CN) older participants in the Harvard Aging Brain Study. We then examined the PACC variations in the Alzheimer's Disease Cooperative Study Prevention Instrument Study as a replication cohort.

RESULTS:

Aß+ CN individuals demonstrated longitudinal decline on all individual PACC components and all PACC variations. Aß group differences emerged earlier when Free and Cued Selective Reminding Test Free Recall was included in the PACC. PACC decline was associated with Clinical Dementia Rating progression.

DISCUSSION:

This independent data set and a replication cohort confirm the ability of the PACC to capture both early and late cognitive decline during the preclinical stages of Alzheimer's disease, which may prove advantageous in the prevention trial design.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos beta-Amiloides / Doença de Alzheimer / Disfunção Cognitiva Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Alzheimers Dement Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos beta-Amiloides / Doença de Alzheimer / Disfunção Cognitiva Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Alzheimers Dement Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos